G1 Therapeutics | search
Click here to view G1 Therapeutics news from 60+ newspapers.
Bookmark or Share- 2024-05-28 | NDAQ:GTHX | Press Release | G1 Therapeutics Inc - StockhouseG1 Therapeutics, Inc. is a commercial-stage oncology biopharmaceutical company whose mission is to develop and deliver next-generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib). The Company is also evaluating therapies in ...
- Overview - G1 Therapeutics, Inc.G1 Therapeutics, Inc. is a commercial-stage oncology biopharmaceutical company whose mission is to develop and deliver next-generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib). The Company is also evaluating therapies in combination with cytotoxic ...
- G1 Therapeutics Inc (GTHX) Stock Price & News - Google FinanceGet the latest G1 Therapeutics Inc (GTHX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
- G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia ...G1 Therapeutics, Inc. is a commercial-stage oncology biopharmaceutical company whose mission is to develop and deliver next-generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib). The Company is also evaluating therapies in combination with cytotoxic ...
- Trilaciclib | intravenous CDK4/6 inhibitor | G1 Therapeutics, Inc.Trilaciclib. Trilaciclib, a transient IV-administered CDK4/6 inhibitor, is a novel therapeutic approach which is given before chemotherapy that temporarily blocks progression through the cell cycle. This provides two potential benefits: (1) bone marrow protection - and therefore the immune system - from damage caused by cytotoxic therapy, and ...
More
